ADC Therapeutics
ADCT
60 hedge funds and large institutions have $149M invested in ADC Therapeutics in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 22 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
2.81% more ownership
Funds ownership: 47.68% → 50.49% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 66 → 60 (-6)
16% less capital invested
Capital invested by funds: $177M → $149M (-$27.4M)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
48% less call options, than puts
Call options by funds: $21K | Put options by funds: $40K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$11.9M |
| 2 |
Goldman Sachs
New York
|
+$8.53M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.79M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$6.39M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.1M |
| 2 |
DM
Deerfield Management
New York
|
-$11.5M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$2.41M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$2.18M |
| 5 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$1.93M |
ADCT Hedge Fund Activity: Q4 2022 in Review
60 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q4 2022, worth a combined $149M — down 16% from $177M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ADCT and 16 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 19 added.
The largest buyer was Millennium Management, adding an estimated $11.9M. The largest seller was Fidelity Investments, cutting an estimated $12.1M.
- 60 institutional investors held ADC Therapeutics (ADCT) as of Q4 2022, down from 66 in Q3 2022.
- Funds reported $149M of ADC Therapeutics stock for Q4 2022, down 16% quarter-over-quarter.
- 16 funds opened new ADC Therapeutics positions in Q4 2022 and 22 closed out, a net change of -6 holders.
- The largest ADC Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $11.9M added.
- The largest ADC Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2022.